Nasdaq
$1.52▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $540.1MShares out 3.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 10.15Pre-market26.10.15 21:436-KKey event#●●●#●●●
Evotec SE
Evotec SE has appointed Dr. Joanna Holbrook as the new Chief Scientific Officer and member of the Management Board, effective November 1, 2026. Additionally, the company disclosed that the Government of Abu Dhabi has exited its position, reducing its voting rights in Evotec from 5.62% to 0%.…more
$1.52+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14After-hours26.10.15 06:00SCHEDULE 13D/AOwnership
Evotec SE
Mubadala Investment Company PJSC and its affiliates have filed an amended Schedule 13D regarding their beneficial ownership of Evotec SE. The filing provides updated information on the directors and executive officers of the reporting entities and confirms the joint filing agreement among the involved parties.…more
$1.52+0.00%vs prev closeView filingShare - 10.14Pre-market26.10.14 19:026-KKey event
Evotec SE
Evotec SE announced preliminary financial results for the first nine months of 2026, reporting revenue of approximately €465.0 million and an adjusted Group EBITDA of approximately -€42.8 million, both exceeding market expectations. The company reaffirmed its full-year 2026 guidance, projecting group revenues between €570 million and €610 million with an adjusted EBITDA of -€70 million to -€105 million.…more
$1.52+0.00%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.9Overnight26.09.09 15:39#●●●#●●●
Evotec Subsidiary Initiates Phase 1 Study for Orthopoxvirus Antibodies
Evotec's subsidiary, Just Biologics, has initiated a Phase 1 clinical trial for antibodies targeting orthopoxviruses under a U.S. Department of Defense program. This study marks a significant step in developing countermeasures against high-priority biological threats.…more
$1.52+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga